$ALOT
AstroNova, Inc.

2015 Q3 Form 10-Q Financial Statement

#000119312515314220 Filed on September 08, 2015

View on sec.gov

Income Statement

Concept 2015 Q3 2015 Q1 2014 Q3
Revenue $23.94M $22.07M $22.37M
YoY Change 7.03% 24.48% 30.08%
Cost Of Revenue $14.09M $13.47M $12.78M
YoY Change 10.29% 32.84% 24.4%
Gross Profit $9.846M $8.600M $9.589M
YoY Change 2.68% 13.31% 38.51%
Gross Profit Margin 41.13% 38.97% 42.87%
Selling, General & Admin $6.447M $6.420M $5.946M
YoY Change 8.43% 7.9% 24.86%
% of Gross Profit 65.48% 74.65% 62.01%
Research & Development $1.565M $1.390M $1.479M
YoY Change 5.81% -4.79% 16.09%
% of Gross Profit 15.89% 16.16% 15.42%
Depreciation & Amortization $490.0K $520.0K $530.0K
YoY Change -7.55% 57.58% 60.61%
% of Gross Profit 4.98% 6.05% 5.53%
Operating Expenses $8.012M $7.810M $7.425M
YoY Change 7.91% 5.4% 23.01%
Operating Profit $1.834M $790.0K $2.164M
YoY Change -15.25% 338.89% 143.97%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $21.00K -$210.0K $83.00K
YoY Change -74.7% 250.0% -432.0%
Pretax Income $1.855M $580.0K $2.247M
YoY Change -17.45% 346.15% 160.67%
Income Tax $687.0K $40.00K $812.0K
% Of Pretax Income 37.04% 6.9% 36.14%
Net Earnings $1.168M $540.0K $1.435M
YoY Change -18.61% -70.97% 106.18%
Net Earnings / Revenue 4.88% 2.45% 6.42%
Basic Earnings Per Share $0.16 $0.19
Diluted Earnings Per Share $0.16 $70.59K $0.18
COMMON SHARES
Basic Shares Outstanding 7.278M shares 7.266M shares 7.704M shares
Diluted Shares Outstanding 7.469M shares 7.916M shares

Balance Sheet

Concept 2015 Q3 2015 Q1 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $18.30M $23.10M $28.00M
YoY Change -34.64% -14.76% -14.11%
Cash & Equivalents $5.056M $7.958M $13.20M
Short-Term Investments $13.30M $15.20M $14.80M
Other Short-Term Assets $7.600M $8.600M $8.000M
YoY Change -5.0% -21.1% -27.93%
Inventory $13.94M $15.58M $16.02M
Prepaid Expenses
Receivables $15.22M $14.11M $14.08M
Other Receivables $400.0K $400.0K $400.0K
Total Short-Term Assets $55.51M $59.29M $66.56M
YoY Change -16.59% -8.83% 0.12%
LONG-TERM ASSETS
Property, Plant & Equipment $8.905M $8.379M $7.783M
YoY Change 14.42% 10.37% 3.91%
Goodwill $4.522M $991.0K $991.0K
YoY Change 356.31% 0.0% 24.65%
Intangibles $6.284M $2.698M $3.049M
YoY Change 106.1% -20.65%
Long-Term Investments
YoY Change
Other Assets $10.98M $6.662M $400.0K
YoY Change 2644.5% 24.8% 300.0%
Total Long-Term Assets $19.88M $15.04M $4.718M
YoY Change 321.43% 181.77% 222.71%
TOTAL ASSETS
Total Short-Term Assets $55.51M $59.29M $66.56M
Total Long-Term Assets $19.88M $15.04M $4.718M
Total Assets $75.40M $74.33M $79.06M
YoY Change -4.63% -4.66% 4.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.369M $3.155M $2.754M
YoY Change 22.33% 32.9% 20.31%
Accrued Expenses $2.464M $2.343M $5.300M
YoY Change -53.51% 1.43% -11.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.873M $9.569M $8.617M
YoY Change 2.97% -3.27% -15.82%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $100.0K
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $1.100M $1.200M $1.000M
YoY Change 10.0% 9.09% -23.08%
Total Long-Term Liabilities $1.100M $1.200M $1.100M
YoY Change 0.0% -14.29% -15.38%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.873M $9.569M $8.617M
Total Long-Term Liabilities $1.100M $1.200M $1.100M
Total Liabilities $10.02M $10.82M $9.837M
YoY Change 1.83% -4.68% -16.75%
SHAREHOLDERS EQUITY
Retained Earnings $41.09M $39.74M $38.69M
YoY Change 6.21% 6.81% 9.63%
Common Stock $479.0K $44.08M $475.0K
YoY Change 0.84% 9378.92% 3.94%
Preferred Stock
YoY Change
Treasury Stock (at cost) $19.60M $19.60M $13.09M
YoY Change 49.74% 57.28% 11.7%
Treasury Stock Shares 2.294M shares 2.294M shares 1.776M shares
Shareholders Equity $65.38M $63.51M $69.22M
YoY Change
Total Liabilities & Shareholders Equity $75.40M $74.33M $79.06M
YoY Change -4.63% -4.66% 4.82%

Cashflow Statement

Concept 2015 Q3 2015 Q1 2014 Q3
OPERATING ACTIVITIES
Net Income $1.168M $540.0K $1.435M
YoY Change -18.61% -70.97% 106.18%
Depreciation, Depletion And Amortization $490.0K $520.0K $530.0K
YoY Change -7.55% 57.58% 60.61%
Cash From Operating Activities $1.190M -$290.0K -$160.0K
YoY Change -843.75% -154.72% -120.51%
INVESTING ACTIVITIES
Capital Expenditures -$640.0K -$530.0K -$580.0K
YoY Change 10.34% 140.91% 123.08%
Acquisitions
YoY Change
Other Investing Activities -$4.110M $2.460M $3.820M
YoY Change -207.59% -144.97% -3572.73%
Cash From Investing Activities -$4.750M $1.940M $3.230M
YoY Change -247.06% -134.09% -997.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -460.0K -6.740M -300.0K
YoY Change 53.33% -67500.0% -30.23%
NET CHANGE
Cash From Operating Activities 1.190M -290.0K -160.0K
Cash From Investing Activities -4.750M 1.940M 3.230M
Cash From Financing Activities -460.0K -6.740M -300.0K
Net Change In Cash -4.020M -5.090M 2.770M
YoY Change -245.13% -1.17% -27800.0%
FREE CASH FLOW
Cash From Operating Activities $1.190M -$290.0K -$160.0K
Capital Expenditures -$640.0K -$530.0K -$580.0K
Free Cash Flow $1.830M $240.0K $420.0K
YoY Change 335.71% -68.0% -59.62%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.05
CY2012Q1 alot Debt Received Upon Sale Of Operation
DebtReceivedUponSaleOfOperation
1000000
CY2015Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7316906 shares
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13199000
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
742239 shares
CY2015Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
2293606 shares
CY2015Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
13000000 shares
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.65
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
304852 shares
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
13.06
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
475776 shares
CY2015Q3 us-gaap Loans Receivable Basis Spread On Variable Rate
LoansReceivableBasisSpreadOnVariableRate
0.02 pure
CY2015Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9576518 shares
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.41
CY2015Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
3741000
CY2015Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2522000
CY2015Q3 us-gaap Stockholders Equity
StockholdersEquity
65379000
CY2015Q3 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
10000000
CY2015Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
44238000
CY2015Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
596000
CY2015Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
643000
CY2015Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
419000
CY2015Q3 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
1072000
CY2015Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3369000
CY2015Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2464000
CY2015Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
41091000
CY2015Q3 us-gaap Liabilities
Liabilities
10017000
CY2015Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
75396000
CY2015Q3 us-gaap Common Stock Value
CommonStockValue
479000
CY2015Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
99000
CY2015Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
29175000
CY2015Q3 us-gaap Liabilities Current
LiabilitiesCurrent
8873000
CY2015Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-827000
CY2015Q3 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
72000
CY2015Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
9962000
CY2015Q3 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
250000
CY2015Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2109647
CY2015Q3 us-gaap Notes Receivable Net
NotesReceivableNet
319000
CY2015Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
10978000
CY2015Q3 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
103000
CY2015Q3 us-gaap Assets
Assets
75396000
CY2015Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
774000
CY2015Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
715000
CY2015Q3 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
14637000
CY2015Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
6284000
CY2015Q3 us-gaap Inventory Net
InventoryNet
13937000
CY2015Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15223000
CY2015Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
305000
CY2015Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8905000
CY2015Q3 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
13274000
CY2015Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
802000
CY2015Q3 us-gaap Treasury Stock Value
TreasuryStockValue
19602000
CY2015Q3 us-gaap Assets Current
AssetsCurrent
55513000
CY2015Q3 us-gaap Inventory Gross
InventoryGross
17678000
CY2015Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
1363000
CY2015Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
6880000
CY2015Q3 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
69000
CY2015Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
6900000
CY2015Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
6284000
CY2015Q3 us-gaap Goodwill
Goodwill
4522000
CY2015Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
816000
CY2015Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3087000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5056000
CY2015Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
769000
CY2015Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
38080000
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2396104
CY2015Q3 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
2636000
CY2015Q3 alot Line Of Credit Receivable Current
LineOfCreditReceivableCurrent
150000
CY2015Q3 alot Funded Debt To Adjusted Ebitda Ratio
FundedDebtToAdjustedEbitdaRatio
1.25 pure
CY2015Q3 alot Revolving Line Of Credit Facility Issued Amount Outstanding
RevolvingLineOfCreditFacilityIssuedAmountOutstanding
150000
CY2015Q3 alot Number Of Installments
NumberOfInstallments
16 Installment
CY2015Q3 alot Fixed Charge Coverage Ratio
FixedChargeCoverageRatio
3 pure
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8341000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
656011 shares
CY2015Q1 us-gaap Treasury Stock Shares
TreasuryStockShares
2293606 shares
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
13000000 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.01
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
72245 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
9.70
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.05
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9544864 shares
CY2015Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
3155000
CY2015Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3302000
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
63511000
CY2015Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
43600000
CY2015Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
702000
CY2015Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
707000
CY2015Q3 us-gaap Inventory Land Held For Sale
InventoryLandHeldForSale
1900000
CY2015Q3 alot Revolving Line Of Credit Facility Issued Maximum Capacity
RevolvingLineOfCreditFacilityIssuedMaximumCapacity
600000
CY2015Q3 alot Amount Of Reserve For Settlement Of Liability
AmountOfReserveForSettlementOfLiability
314000
CY2015Q3 alot Product Replacement Cost Charged Against Reserve
ProductReplacementCostChargedAgainstReserve
358000
CY2015Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
621000
CY2015Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3155000
CY2015Q1 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
1167000
CY2015Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2343000
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
39735000
CY2015Q1 us-gaap Liabilities
Liabilities
10819000
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
74330000
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
477000
CY2015Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
148000
CY2015Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
28444000
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
9569000
CY2015Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-699000
CY2015Q1 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
83000
CY2015Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
10600000
CY2015Q1 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
255000
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3225000
CY2015Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4033000
CY2015Q1 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
88000
CY2015Q1 us-gaap Assets
Assets
74330000
CY2015Q1 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
18202000
CY2015Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2698000
CY2015Q1 us-gaap Inventory Net
InventoryNet
15582000
CY2015Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
14107000
CY2015Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8379000
CY2015Q1 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
15174000
CY2015Q1 us-gaap Treasury Stock Value
TreasuryStockValue
19602000
CY2015Q1 us-gaap Assets Current
AssetsCurrent
61918000
CY2015Q1 us-gaap Inventory Gross
InventoryGross
18737000
CY2015Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
3028000
CY2015Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
3400000
CY2015Q1 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
256000
CY2015Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
7372000
CY2015Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2698000
CY2015Q1 us-gaap Goodwill
Goodwill
991000
CY2015Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
765000
CY2015Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4140000
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7958000
CY2015Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
36823000
CY2015Q1 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
2629000
CY2015Q1 us-gaap Inventory Land Held For Sale
InventoryLandHeldForSale
1900000
CY2015Q1 alot Line Of Credit Receivable Current
LineOfCreditReceivableCurrent
173000
CY2012Q1 alot Loan Receivable Interest Rate Stated Percentage
LoanReceivableInterestRateStatedPercentage
0.0375 pure
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.33
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2655000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.016 pure
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
150000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.268 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.020 pure
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
230706 shares
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.14
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7883000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7652000 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.34
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.330 pure
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
874000
us-gaap Net Income Loss
NetIncomeLoss
2564000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-43000
us-gaap Sales Revenue Net
SalesRevenueNet
43140000
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
1076000
us-gaap Operating Income Loss
OperatingIncomeLoss
3863000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
845000
us-gaap Gross Profit
GrossProfit
18225000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-38000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2709000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2521000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-41000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
3825000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2776000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
1267000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
3945000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
3825000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1261000
us-gaap Share Based Compensation
ShareBasedCompensation
259000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
8878000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
4858000
us-gaap Operating Expenses
OperatingExpenses
14362000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
7401000
us-gaap Proceeds From Sale And Collection Of Notes Receivable
ProceedsFromSaleAndCollectionOfNotesReceivable
165000
us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
-100000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-173000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2850000
us-gaap Decrease In Restricted Cash
DecreaseInRestrictedCash
1800000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-191000
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
112000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
903000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2634000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-1555000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
285000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
7900000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
351000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
24915000
us-gaap Employee Stock Ownership Plan Esop Compensation Expense
EmployeeStockOwnershipPlanESOPCompensationExpense
3000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1038000
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
51000
us-gaap Restricted Stock Expense
RestrictedStockExpense
144000
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
alot Proceeds From Disposition Of Inventory
ProceedsFromDispositionOfInventory
2355000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.32
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>(1) Overview</b></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Headquartered in West Warwick, Rhode Island, Astro-Med Inc. designs, develops, manufactures and distributes a broad range of specialty printers and data acquisition and analysis systems. Our products are distributed through our own sales force and authorized dealers in the United States. We also sell to customers outside of the United States primarily through our Company offices in Canada, Mexico, Europe and Southeast Asia as well as with independent dealers and representatives. Astro-Med, Inc. products are sold under the brand names Astro-Med&#xA0;<sup style="font-size:85%; vertical-align:top">&#xAE;</sup> Test&#xA0;&amp; Measurement and QuickLabel&#xA0;<sup style="font-size:85%; vertical-align:top">&#xAE;</sup> Systems and are employed around the world in a wide range of aerospace, apparel, automotive, avionics, chemical, computer peripherals, communications, distribution, food and beverage, general manufacturing, packaging and transportation applications.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Unless otherwise indicated, references to &#x201C;Astro-Med,&#x201D; the &#x201C;Company,&#x201D; &#x201C;we,&#x201D; &#x201C;our,&#x201D; and &#x201C;us&#x201D; in this Quarterly Report on Form&#xA0;10-Q refer to Astro-Med, Inc. and its consolidated subsidiaries.</p> </div>
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
4159000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
244072 shares
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
us-gaap Line Of Credit Facility Interest Rate Description
LineOfCreditFacilityInterestRateDescription
Any borrowings made under this line of credit bear interest at either a fluctuating base rate equal to the highest of (i) the Prime Rate, (ii) 1.50% above the daily one month LIBOR, and (iii) the Federal Funds Rate in effect plus 1.50% or at a fixed rate of LIBOR plus an agreed upon margin of between 0% and 2.25%, based on the Company's funded debt to EBITDA ratio as defined in the agreement.
dei Amendment Flag
AmendmentFlag
false
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.016 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
700 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
424100 shares
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0000008146
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y1M6D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
2800 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y7M6D
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
12.61
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
190676 shares
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.14
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
8665 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
7.93
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.227 pure
us-gaap Fair Value Inputs Discount Rate
FairValueInputsDiscountRate
0.155 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.020 pure
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
13.98
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--01-31
us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2016-01-31
dei Entity Registrant Name
EntityRegistrantName
ASTRO MED INC /NEW/
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7459000 shares
us-gaap Line Of Credit Facility Expiration Period
LineOfCreditFacilityExpirationPeriod
P3Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
110000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
13.95
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
2093 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.24
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7269000 shares
dei Document Period End Date
DocumentPeriodEndDate
2015-08-01
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
10.07
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
14.05
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
20979 shares
dei Trading Symbol
TradingSymbol
ALOT
us-gaap Fair Value Measurements Significant Assumptions
FairValueMeasurementsSignificantAssumptions
Key assumptions include (1) a weighted average cost of capital of 15.5%; (2) a range of earnings projections from $110,000-$700,000 and (3) a range of contract renewal probability from 0%-100%.
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.33
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1158000
us-gaap Share Based Compensation
ShareBasedCompensation
444000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.327 pure
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 Segment
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1291000
us-gaap Net Income Loss
NetIncomeLoss
2378000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-128000
us-gaap Sales Revenue Net
SalesRevenueNet
46144000
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
1022000
us-gaap Operating Income Loss
OperatingIncomeLoss
3282000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1646000
us-gaap Gross Profit
GrossProfit
18876000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
254000
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
7360000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1067000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-15000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2250000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-113000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
3536000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
264000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
191000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
3127000
us-gaap Line Of Credit Facility Average Outstanding Amount
LineOfCreditFacilityAverageOutstandingAmount
0
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
3536000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
8992000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2902000
us-gaap Operating Expenses
OperatingExpenses
15594000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-6567000
us-gaap Proceeds From Sale And Collection Of Notes Receivable
ProceedsFromSaleAndCollectionOfNotesReceivable
208000
us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
-135000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-825000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3361000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-842000
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
144000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
197000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3241000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
863000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
331000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
5003000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
194000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
27268000
us-gaap Employee Stock Ownership Plan Esop Compensation Expense
EmployeeStockOwnershipPlanESOPCompensationExpense
4000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
946000
us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-18000
us-gaap Restricted Stock Expense
RestrictedStockExpense
296000
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
alot Fees To Non Employee Director
FeesToNonEmployeeDirector
7000
alot Non Employee Director Received Restricted Stock Award Value
NonEmployeeDirectorReceivedRestrictedStockAwardValue
20000
alot Loan Receivable Date Considered For Interest Payments
LoanReceivableDateConsideredForInterestPayments
2013-01-30
alot Reservation Of Shares Under Employee Stock Purchase Plan
ReservationOfSharesUnderEmployeeStockPurchasePlan
247500 shares
alot Maximum Disposal Restriction As Percentage Of Restricted Stock Units
MaximumDisposalRestrictionAsPercentageOfRestrictedStockUnits
0.50 pure
alot Number Of Equity Incentive Plans
NumberOfEquityIncentivePlans
2 Equity_Plan
alot Period To Receive Lower Product Prices From Supplier Description
PeriodToReceiveLowerProductPricesFromSupplierDescription
Through fiscal 2017
CY2014Q1 alot Settlement Amount Received From Supplier For Recovery Of Cost And Expenses
SettlementAmountReceivedFromSupplierForRecoveryOfCostAndExpenses
450000
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y2M12D
CY2013Q2 alot Estimated Replacement Cost Of Product
EstimatedReplacementCostOfProduct
672000
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.93
CY2014Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.18
CY2014Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
150000 shares
CY2014Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
212176 shares
CY2014Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.07
CY2014Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7916000 shares
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
8012000
CY2014Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7704000 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.84
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
1435000
CY2014Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-132000
CY2014Q3 us-gaap Sales Revenue Net
SalesRevenueNet
22366000
CY2014Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.19
CY2014Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.361 pure
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
2164000
CY2014Q3 us-gaap Gross Profit
GrossProfit
9589000
CY2014Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
83000
CY2014Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000
CY2014Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1303000
CY2014Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-133000
CY2014Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
2247000
CY2014Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
2247000
CY2014Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
812000
CY2014Q3 us-gaap Share Based Compensation
ShareBasedCompensation
128000
CY2014Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4503000
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
7425000
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1479000
CY2014Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
59000
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1443000
CY2014Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
175000
CY2014Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
12777000
CY2014Q3 us-gaap Employee Stock Ownership Plan Esop Compensation Expense
EmployeeStockOwnershipPlanESOPCompensationExpense
2000
CY2014Q3 us-gaap Restricted Stock Expense
RestrictedStockExpense
67000
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.43
CY2015Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.16
CY2015Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
424100 shares
CY2015Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
190934 shares
CY2015Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.07
CY2015Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7469000 shares
CY2015Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7278000 shares
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.44
CY2015Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.16
CY2015Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.370 pure
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
1168000
CY2015Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-118000
CY2015Q3 us-gaap Sales Revenue Net
SalesRevenueNet
23938000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
1834000
CY2015Q3 us-gaap Gross Profit
GrossProfit
9846000
CY2015Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
21000
CY2015Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
4000
CY2015Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1050000
CY2015Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-122000
CY2015Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1855000
CY2015Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1855000
CY2015Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
687000
CY2015Q3 us-gaap Share Based Compensation
ShareBasedCompensation
301000
CY2015Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4664000
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1565000
CY2015Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
70000
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1783000
CY2015Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
105000
CY2015Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
14092000
CY2015Q3 us-gaap Employee Stock Ownership Plan Esop Compensation Expense
EmployeeStockOwnershipPlanESOPCompensationExpense
3000
CY2015Q3 us-gaap Restricted Stock Expense
RestrictedStockExpense
228000
CY2015Q3 alot Non Employee Director Received Restricted Stock Award Value
NonEmployeeDirectorReceivedRestrictedStockAwardValue
7115

Files In Submission

Name View Source Status
0001193125-15-314220-index-headers.html Edgar Link pending
0001193125-15-314220-index.html Edgar Link pending
0001193125-15-314220.txt Edgar Link pending
0001193125-15-314220-xbrl.zip Edgar Link pending
alot-20150801.xml Edgar Link completed
alot-20150801.xsd Edgar Link pending
alot-20150801_cal.xml Edgar Link unprocessable
alot-20150801_def.xml Edgar Link unprocessable
alot-20150801_lab.xml Edgar Link unprocessable
alot-20150801_pre.xml Edgar Link unprocessable
d66587d10q.htm Edgar Link pending
d66587dex311.htm Edgar Link pending
d66587dex312.htm Edgar Link pending
d66587dex321.htm Edgar Link pending
d66587dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending